| Name | Title | Contact Details |
|---|
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.
Daewoong Pharmaceutical Co. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Venture Technology Group is a Farmington Hills, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Roxane Laboratories is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BCM GROUP is a Hamburg, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.